Compare Gilead Sciences, Inc. (GILD) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Microchip Technology Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.31 (market cap $168.35B), while Microchip Technology Inc. trades at $79.5 (market cap $43.99B). The key difference: Gilead Sciences, Inc. is far larger — about 3.8× Microchip Technology Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MCHP | |
|---|---|---|
Market Cap | $168.35B | $43.99B |
Sector | Health | Technology |
52-Week High | $155.80 | $102.97 |
52-Week Low | $110.56 | $49.02 |
Enterprise Value | $191.42B | $49.12B |
Dividend Yield | 2.42% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Microchip Technology (MCHP) trades at $80.11, down 1.57% over the past day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust data center revenue growth, including a 98% surge last quarter, highlight operational momentum. The company maintains solid cash flow and a healthy balance sheet, though elevated valuation ratios like a P/E of 119.15 warrant caution.
Outlook remains positive driven by AI and data center demand, with a consensus price target of $104 implying significant upside. Risks include high debt levels and sensitivity to semiconductor cycles. Institutional sentiment is strong with no sell ratings among 44 analysts, supporting a favorable investment case amid broader tech recovery trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
